- Home
- -
Bioscience
Biography
I am a trained immunologist and vaccinologist having undertaken DPhil on malaria transmission-blocking vaccines at the University of Oxford. Following on from this, I served as a post-doc with Kevin Marsh and Philip Bejon at the KEMRI-Wellcome Trust Research Programme in Kilifi working on assessing the infectious reservoir of malaria. From 2015, portfolio of work expanded to setting up currently the largest single-site falciparum controlled human malaria infection study in 161 volunteers leading a diverse team in Kenya in collaboration with key partners in this field.
Biography
I am a trained immunologist and vaccinologist having undertaken DPhil on malaria transmission-blocking vaccines at the University of Oxford. Following on from this, I served as a post-doc with Kevin Marsh and Philip Bejon at the KEMRI-Wellcome Trust Research Programme in Kilifi working on assessing the infectious reservoir of malaria. From 2015, portfolio of work expanded to setting up currently the largest single-site falciparum controlled human malaria infection study in 161 volunteers leading a diverse team in Kenya in collaboration with key partners in this field.
Current Work
- Interrogating immunity (vaccine-induced and naturally acquired) to malaria (utilising CHMI vaccine efficacy model; CHMI transmission model, malaria surveillance cohort, previous cross-sectional and longitudinal cohorts (AFIRM and LAMB cohorts) and Shigella (utilising Shigella HIS and archived samples from Biobank) – protein production, microarray, mass spectrometry and cytometry, systems serology, RNA sequencing
- Understanding role of microbiome influence in host immunity (utilising Shigella HIS and archived samples from Biobank) – NGS Identification of molecular markers of malaria transmission – RNA sequencing (transcriptomics), cDNA microarray, and mosquito feeding assays Utilisation of a structure-aided approach to vaccine design for malaria transmission and Shigella – cell sorting, BCR sequencing, and monoclonal antibody production
Collaborations
Project Research
No active details yet
Videos
Publications
Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.
Rosenkranz, M., Nkumama, I. N., Ogwang, R., Kraker, S., Blickling, M., Mwai, K., Odera, D., Tuju, J., Fürle, K., Frank, R., Chepsat, E., Kapulu, M. C., Study Team, C. S., Osier, F. H.
Life Sci Alliance, (2024). 7:
Full-length MSP1 is a major target of protective immunity after controlled human malaria infection.
Rosenkranz, M., Nkumama, I. N., Ogwang, R., Kraker, S., Blickling, M., Mwai, K., Odera, D., Tuju, J., Fürle, K., Frank, R., Chepsat, E., Kapulu, M. C., Study Team, C. S., Osier, F. H.
Life Sci Alliance, (2024). 7:
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama, I. N., Ogwang, R., Odera, D., Musasia, F., Mwai, K., Nyamako, L., Murungi, L., Tuju, J., Fürle, K., Rosenkranz, M., Kimathi, R., Njuguna, P., Hamaluba, M., Kapulu, M. C., Frank, R., Osier, F. H. A.
Immunity, (2024). :
Reversible host cell surface remodelling limits immune recognition and maximizes transmission of Plasmodium falciparum gametocytes.
Ngotho, P., Press, K. D., Peedell, M., Muasya, W., Omondi, B. R., Otoboh, S. E., Seydel, K. B., Kapulu, M., Laufer, M., Taylor, T., Bousema, T., Marti, M.
bioRxiv, (2024). :
Safety and immunogenicity of varied doses of R21/Matrix-Mâ„¢ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.
Sang, S., Datoo, M. S., Otieno, E., Muiruri, C., Bellamy, D., Gathuri, E., Ngoto, O., Musembi, J., Provstgaard-Morys, S., Stockdale, L., Aboagye, J., Woods, D., Lawrie, A., Roberts, R., Keter, K., Kimani, D., Ndungu, F., Kapulu, M., Njau, I., Orindi, B., Ewer, K. J., Hill, A. V. S., Bejon, P., Hamaluba, M.
Wellcome Open Res, (2023). 8:450